β-adrenoreceptors and the risk of Parkinson's disease

Hopfner, Franziska; Höglinger, Günter U.; Kuhlenbäumer, Gregor; Pottegård, Anton; Wod, Mette; Christensen, Kaare; Tanner, Caroline M.; Deuschl, Günther

doi:10.1016/s1474-4422(19)30400-4

Cited by 50 publications

(40 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a recent study of a huge cohort of 1.6 million subjects reported that the physiological human appendix contains intraneuronal α-synuclein and misfolded aggregates, and that removing the appendix early in life reduces the risk of developing PD [135]. Lastly, any causal association between beta-2-adrenoreceptor antagonist (beta-blocker) and higher risk for PD appears weak in terms of its evidence [136].…”

Section: Additional Features With Class I Evidencementioning

confidence: 99%

Non-genetic risk and protective factors and biomarkers for neurological disorders: a meta-umbrella systematic review of umbrella reviews

Mentis

Dardiotis

Efthymiou

et al. 2021

BMC Med

View full text Add to dashboard Cite

Background The etiologies of chronic neurological diseases, which heavily contribute to global disease burden, remain far from elucidated. Despite available umbrella reviews on single contributing factors or diseases, no study has systematically captured non-purely genetic risk and/or protective factors for chronic neurological diseases. Methods We performed a systematic analysis of umbrella reviews (meta-umbrella) published until September 20th, 2018, using broad search terms in MEDLINE, SCOPUS, Web of Science, Cochrane Database of Systematic Reviews, Cumulative Index to Nursing and Allied Health Literature, ProQuest Dissertations & Theses, JBI Database of Systematic Reviews and Implementation Reports, DARE, and PROSPERO. The PRISMA guidelines were followed for this study. Reference lists of the identified umbrella reviews were also screened, and the methodological details were assessed using the AMSTAR tool. For each non-purely genetic factor association, random effects summary effect size, 95% confidence and prediction intervals, and significance and heterogeneity levels facilitated the assessment of the credibility of the epidemiological evidence identified. Results We identified 2797 potentially relevant reviews, and 14 umbrella reviews (203 unique meta-analyses) were eligible. The median number of primary studies per meta-analysis was 7 (interquartile range (IQR) 7) and that of participants was 8873 (IQR 36,394). The search yielded 115 distinctly named non-genetic risk and protective factors with a significant association, with various strengths of evidence. Mediterranean diet was associated with lower risk of dementia, Alzheimer disease (AD), cognitive impairment, stroke, and neurodegenerative diseases in general. In Parkinson disease (PD) and AD/dementia, coffee consumption, and physical activity were protective factors. Low serum uric acid levels were associated with increased risk of PD. Smoking was associated with elevated risk of multiple sclerosis and dementia but lower risk of PD, while hypertension was associated with lower risk of PD but higher risk of dementia. Chronic occupational exposure to lead was associated with higher risk of amyotrophic lateral sclerosis. Late-life depression was associated with higher risk of AD and any form of dementia. Conclusions We identified several non-genetic risk and protective factors for various neurological diseases relevant to preventive clinical neurology, health policy, and lifestyle counseling. Our findings could offer new perspectives in secondary research (meta-research).

show abstract

Section: Additional Features With Class I Evidencementioning

confidence: 99%

Non-genetic risk and protective factors and biomarkers for neurological disorders: a meta-umbrella systematic review of umbrella reviews

Mentis

Dardiotis

Efthymiou

et al. 2021

BMC Med

View full text Add to dashboard Cite

show abstract

“…The association of beta-blockers with Parkinson's disease has been controversial, with a recent review concluding that much of the reported association is probably a result of reverse causation (beta-blockers are used to treat tremor) and confounded by differential rates of smoking. 11 However, our data cannot readily be explained in this way, because all patients at baseline were free of movement disorder, including tremor, and cohorts were matched for rates of nicotine dependence. We confirmed earlier findings that CCBs are more effective than beta-blockers in prevention of stroke, 4 likely because CCBs decrease blood pressure variability, whereas beta-blockers increase it.…”

Section: Discussionmentioning

confidence: 94%

Incidence of neurodegenerative and cerebrovascular diseases associated with antihypertensive drug classes

2021

View full text Add to dashboard Cite

Antihypertensive drugs (AHTs) are associated with lowered risks of neurodegenerative diseases and stroke. However, the relative risks associated with different AHT classes are unclear. Using an electronic health record network with 34 million eligible patients, we compared rates of these disorders over a 2-year period, in propensity score-matched cohorts of people taking calcium channel blockers (CCBs) compared with those taking other AHT classes. CCBs were associated with a higher incidence of all disorders compared with renin-angiotensin system agents, and a higher incidence of dementia and cerebrovascular disease compared with diuretics. CCBs were associated with a lower incidence of movement disorders and cerebrovascular disease compared with beta-blockers. The data show that AHT classes confer differential risks of neurodegenerative and cerebrovascular diagnoses.

show abstract

“…Patients treated with propranolol have been shown to have a reduced risk of developing Parkinson's disease. For this reason, most clinicians do not change their therapeutic strategy [67].…”

Section: Parkinson's Diseasementioning

confidence: 99%

Neuropsychiatric Consequences of Lipophilic Beta-Blockers

et al. 2021

View full text Add to dashboard Cite

Beta-blockers are a class of drugs with important benefits in cardiovascular pathology. In this paper, we aim to highlight their adverse and therapeutic effects in the neuropsychiatric field. With respect to permeability, we would like to mention that most beta-blockers are lipophilic and can cross the blood–brain barrier. Observational studies show the presence of neuropsychiatric side effects when taking beta-blockers, and is the reason for which caution is recommended in their use in patients with depressive syndrome. From a therapeutic point of view, most current evidence is for the use of beta-blockers in migraine attacks, essential tremor, and akathisia. Beta-blockers appear to be effective in the treatment of aggressive behavior, beneficial in the prevention of posttraumatic stress syndrome and may play a role in the adjuvant treatment of obsessive–compulsive disorder, which is refractory to standard therapy. In conclusion, the relationship between beta-blockers and the central nervous system appears as a two-sided coin. Summarizing the neuropsychiatric side effects of beta-blockers, we suggest that clinicians pay special attention to the pharmacological properties of different beta-blockers.

show abstract

β-adrenoreceptors and the risk of Parkinson's disease

Cited by 50 publications

References 57 publications

Non-genetic risk and protective factors and biomarkers for neurological disorders: a meta-umbrella systematic review of umbrella reviews

Non-genetic risk and protective factors and biomarkers for neurological disorders: a meta-umbrella systematic review of umbrella reviews

Incidence of neurodegenerative and cerebrovascular diseases associated with antihypertensive drug classes

Neuropsychiatric Consequences of Lipophilic Beta-Blockers

Contact Info

Product

Resources

About